Alternate-weekly medication dosing for weight maintenance.

A phase 2 randomised, open-label trial of maintenance of weight loss with alternate-weekly incretin medication dosing in adults currently taking semaglutide or tirzepatide for obesity management.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12625000609459

Enrollment

Registered

2025-06-12

Start date

2025-09-17

Completion date

2026-06-26

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The overall aim of this study is to establish the feasibility of a treatment approach using alternate-weekly dosing of incretin medication for weight maintenance after weight loss.

Interventions

Semaglutide or tirzepatide administered at reduced frequency (fortnightly) for 24 weeks. The dose administered every fortnight will be the numerical weekly dose at recruitment, but given every fortnight rather than weekly. Subcutaneous injection. Adherence based on self-report.

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Age 18 years or older Currently taking once-weekly semaglutide or tirzepatide for weight management, at a stable dose Has lost greater than or equal to 10% total body weight during current weight loss attempt Stable weight leading up to enrolment

Exclusion criteria

Planned bariatric surgery during follow-up Clinical indication for continuation of weekly dosing

Outcome results